12/20
07:27 am
aapg
Ascentage Pharma Group International (NASDAQ:AAPG) was upgraded by analysts at Lucid Cap Mkts to a "strong-buy" rating.
Medium
Report
Ascentage Pharma Group International (NASDAQ:AAPG) was upgraded by analysts at Lucid Cap Mkts to a "strong-buy" rating.
12/17
08:00 am
aapg
Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference
12/8
07:45 pm
aapg
ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
Medium
Report
ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
12/8
07:45 pm
aapg
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP
Medium
Report
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP
12/8
07:45 pm
aapg
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
Medium
Report
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
12/7
08:10 pm
aapg
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
Medium
Report
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
12/6
10:15 am
aapg
Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting
Medium
Report
Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting
12/4
07:00 pm
aapg
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA
Medium
Report
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA
12/4
07:04 am
aapg
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
Medium
Report
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
12/1
08:00 am
aapg
Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025
Neutral
Report
Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025
11/24
07:00 pm
aapg
Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy
Low
Report
Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy
11/24
09:04 am
aapg
Ascentage Pharma Group International (NASDAQ:AAPG) was given a new $51.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Ascentage Pharma Group International (NASDAQ:AAPG) was given a new $51.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
aapg
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Medium
Report
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/19
08:00 am
aapg
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025
Low
Report
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025
11/10
08:03 am
aapg
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at BTIG Research. They set a "buy" rating and a $50.00 price target on the stock.
Low
Report
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at BTIG Research. They set a "buy" rating and a $50.00 price target on the stock.
11/6
06:56 am
aapg
Ascentage Pharma Group International (NASDAQ:AAPG) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Low
Report
Ascentage Pharma Group International (NASDAQ:AAPG) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
11/5
06:01 am
aapg
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Low
Report
Ascentage Pharma Group International (NASDAQ:AAPG) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
11/3
08:10 pm
aapg
Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025
Medium
Report
Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025
11/3
08:10 pm
aapg
Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025
Medium
Report
Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025
10/29
08:00 pm
aapg
Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025
Low
Report
Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025
10/7
08:00 am
aapg
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025
Medium
Report
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025